Affordable and scanner agnostic image analysis solutions utilizing artificial intelligence for colorimetric and morphometric analysis for oncology, neuroscience and toxicological pathology SUNNYVALE, CA--(BUSINESS WIRE)—OptraSCAN, Inc....

OptraSCANTM On-Demand Digital Pathology announced today the availability of a Breast Cancer Focused Panel of Algorithmic Biomarkers (ER/PR, HER-2/neu, Ki67, P53, EGFR, AE1/AE3) through its OptraASSAYSTM and OptraCARDSTM Solutions, as part of...

More news from Philips this week - announcing a licensing agreement with Visiopharm to combine Visiopharm's breast cancer panel with Philips' Intellisite digital pathology solution. From a scientific standpoint, as the references mentioned...

Leica Biosystems was kind enough to share with me a recent white paper on "Use of Aperio Image Analysis in Peer Reviewed Breast Cancer Research" This is a lengthy review of 30 articles published in peer-reviewed scientific journals, which...

Quantification Algorithms: Value and Progress in Standardization of IHC Breast Tissue Data April 13th, 2016 12:00 PM EST Michael Grunkin, Ph.D. Chief Executive Officer Visiopharm In collaboration with Visiopharm®, Dynamyx™ software...

Carlsbad, CA. – April 16, 2015 – Applied Spectral Imaging (ASI, www.spectral-imaging.com) announced today that it has received clearance from the South Korean Ministry of Food and Drug Safety (MFDS) for its GenASIs HiPath image capture and...